Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | HRH1 | P35367 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8201616 | 1.00 | KMT2A (0.46) | KMT2AHTR2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL2696782 | 1.00 | KMT2A (0.46) | KMT2AHTR2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5061699 | 1.00 | KMT2A (0.46) | KMT2AHTR2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL20384849 | 0.94 | KMT2A (0.42) | KMT2AHTR2AGRIN2DGRIN3BGRIN1 | |
| Benzonitrile SCHEMBL8546884 | 0.84 | TSHR (0.47) | KMT2AHTR2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL31546141 | 0.78 | KMT2A (0.39) | KMT2A | |
| SCHEMBL7108519 | 0.77 | IDO1 (0.47) | HTR2A | |
| SCHEMBL28971366 | 0.77 | IDO1 (0.47) | HTR2A | |
| SCHEMBL5852603 | 0.77 | IDO1 (0.47) | HTR2A | |
| SCHEMBL1109727 | 0.77 | IDO1 (0.47) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0658537-B1 | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI KAGAKU KK (JP) | 1999-03-31 | — | — | EP | claimed |
| EP-0658537-A1 | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-06-21 | — | — | EP | claimed |
| US-20130131034-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-05-23 | — | — | US | disclosed |
| EP-1849778-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE EPOXY COMPOUND, COMPLEX FOR USE IN THE PROCESS, AND PROCESS FOR PRODUCING THE SAME | JAPAN SCIENCE & TECH AGENCY (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-8410295-B2 | Method for production of optically active epoxy compound, and complex used therefor and process for producing the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410295-B2 | Method for production of optically active epoxy compound, and complex used therefor and process for producing the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2013-04-02 | — | — | US | disclosed |
| EP-2542524-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-01-09 | — | — | EP | disclosed |
| US-20120178954-A1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND, AND COMPLEX USED THEREFOR AND PROCESS FOR PRODUCING THE SAME | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20120178954-A1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND, AND COMPLEX USED THEREFOR AND PROCESS FOR PRODUCING THE SAME | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8163941-B2 | Reacting an unsaturated compound with oxidier in presence of a oxidation catalyst | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163941-B2 | Reacting an unsaturated compound with oxidier in presence of a oxidation catalyst | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-04-24 | — | — | US | disclosed |
| US-5760242-A | Method of producing a cis-oxazoline | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5760242-A | Method of producing a cis-oxazoline | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1998-06-02 | — | — | US | disclosed |
| EP-0816317-A1 | PROCESS FOR PRODUCING TRANS-2-BROMOINDAN-1-OL | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0784698-A1 | BIOLOGICAL RESOLUTION OF RACEMIC INDENE OXIDE TO (1S,2R)-INDENE OXIDE | Merck & Co., Inc. (US) | 1997-07-23 | — | — | EP | disclosed |
| US-5648534-A | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1997-07-15 | — | — | US | disclosed |
| US-5648534-A | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1997-07-15 | — | — | US | disclosed |
| WO-1996012818-A1 | BIOLOGICAL RESOLUTION OF RACEMIC INDENE OXIDE TO (1S,2R)-INDENE OXIDE | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0658537-A1 | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-06-21 | — | — | EP | disclosed |
| EP-0658537-A1 | Method of producing cis-1-aminoindan-2-ol | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131034-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | ANXA2, ANXA3, ADM2 | KMT2A 2830/4885HTR2A 464/4885GRIN2D 748/4885 |
| US-20120178954-A1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND, AND COMPLEX USED THEREFOR AND PROCESS FOR PRODUCING THE SAME | CYP4F11, CYP51A1, COASY | KMT2A 2928/4885HTR2A 3154/4885GRIN2D 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.